Literature DB >> 30292861

A novel tool to evaluate the implant position and predict defibrillation success of the subcutaneous implantable cardioverter-defibrillator: The PRAETORIAN score.

Anne-Floor B E Quast1, Sarah W E Baalman2, Tom F Brouwer2, Lonneke Smeding2, Arthur A M Wilde2, Martin C Burke3, Reinoud E Knops2.   

Abstract

BACKGROUND: Suboptimal positioning of the subcutaneous implantable cardioverter-defibrillator (S-ICD) increases the defibrillation threshold and risk of conversion failure.
OBJECTIVE: Our objective is to develop a tool to evaluate the implant position and predict defibrillation success of the S-ICD: the PRAETORIAN score.
METHODS: The PRAETORIAN score is based on clinical and computer modeling knowledge of determinants affecting the defibrillation threshold: subcoil fat, subgenerator fat, and anterior positioning of the S-ICD generator. The score evaluates these determinants on the postoperative anterior-posterior and lateral chest radiographs and has 3 categories: 30-<90 points representing a low risk, 90-<150 points representing an intermediate risk, and ≥150 points representing a high risk of conversion failure. The score was developed using 2 separate S-ICD data sets for derivation and validation. The performance metrics are the positive and negative predictive values.
RESULTS: The development data set consisted of 181 patients with S-ICD, and the validation cohort consisted of 321 patients from the S-ICD Investigational Device Exemption trial. The distribution of scores was 93%-98% low risk (<90 points), 2%-5% intermediate risk (90-<150 points), and 1% high risk (≥150 points). The positive predictive value for an intermediate or high PRAETORIAN score for a failed conversion test was 51%, while a low PRAETORIAN score predicted a successful conversion in 99.8% of patients.
CONCLUSION: The PRAETORIAN score allows the identification of patients with high defibrillation thresholds by using the routine chest radiograph and provides feedback to implanters on S-ICD positioning. The PRAETORIAN-DFT trial will prospectively validate the score by randomizing to standard conversion testing vs using the score without conversion testing.
Copyright © 2018 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Conversion testing; Defibrillation testing; Implantation; Subcutaneous implantable cardioverter-defibrillator

Year:  2018        PMID: 30292861     DOI: 10.1016/j.hrthm.2018.09.029

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  14 in total

Review 1.  Pregnancy in patients with implantable cardiac defibrillators.

Authors:  Geoffrey R Wong; Megan Ang; Jasveer Jayarajan; Fiona Walker; Pier D Lambiase
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-05-10

Review 2.  Innovations in Cardiac Implantable Electronic Devices.

Authors:  Khurrum Khan; Jitae A Kim; Andra Gurgu; Muzamil Khawaja; Dragos Cozma; Mihail G Chelu
Journal:  Cardiovasc Drugs Ther       Date:  2021-03-02       Impact factor: 3.947

3.  Successful defibrillation verification in subcutaneous implantable cardioverter-defibrillator recipients by low-energy shocks.

Authors:  Mauro Biffi; Matteo Ziacchi; Andrea Angeletti; Andrea Castelli; Giulia Massaro; Cristian Martignani; Mariolina Lovecchio; Sergio Valsecchi; Igor Diemberger
Journal:  Clin Cardiol       Date:  2019-04-25       Impact factor: 2.882

4.  Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.

Authors:  Federico Migliore; Giulia Mattesi; Pietro De Franceschi; Giuseppe Allocca; Martino Crosato; Vittorio Calzolari; Mauro Fantinel; Benedetta Ortis; Domenico Facchin; Elisabetta Daleffe; Tommaso Fabris; Elena Marras; Manuel De Lazzari; Francesco Zanon; Lina Marcantoni; Mariachiara Siciliano; Domenico Corrado; Sabino Iliceto; Emanuele Bertaglia; Massimo Zecchin
Journal:  J Cardiovasc Electrophysiol       Date:  2019-03-13

5.  The "Defibrillation Testing, Why Not?" survey. Testing of subcutaneous and transvenous defibrillators in the Italian clinical practice.

Authors:  Federico Migliore; Stefano Viani; Matteo Ziacchi; Luca Ottaviano; Pietro Francia; Valter Bianchi; Silvana De Bonis; Paolo De Filippo; Gianfranco Tola; Alessandro Vicentini; Erika Taravelli; Valeria Ilia Calvi; Mariolina Lovecchio; Sergio Valsecchi; Giovanni Luca Botto
Journal:  Int J Cardiol Heart Vasc       Date:  2022-01-11

6.  Ultrasound-guided intermuscular pocket creation for a subcutaneous implantable cardioverter-defibrillator.

Authors:  Yusuke Sonoda; Koji Fukuzawa; Yu Izawa; Jun Sakai; Ken-Ichi Hirata
Journal:  HeartRhythm Case Rep       Date:  2021-11-18

7.  High shock impedance during subcutaneous implantable defibrillator generator replacements: Authors' reply.

Authors:  Willeke van der Stuijt; Lonneke Smeding; Reinoud E Knops
Journal:  Europace       Date:  2022-02-02       Impact factor: 5.214

8.  Sudden depression of R-wave amplitude in a patient who underwent subcutaneous implantable cardioverter-defibrillator implantation.

Authors:  Masaki Takahashi; Hidekazu Kondo; Tetsuji Shinohara; Naohiko Takahashi
Journal:  HeartRhythm Case Rep       Date:  2021-04-15

Review 9.  State-of-the-art consensus on non-transvenous implantable cardioverter-defibrillator therapy.

Authors:  Christoph Schukro; David Santer; Günther Prenner; Markus Stühlinger; Martin Martinek; Alexander Teubl; Deddo Moertl; Stefan Schwarz; Michael Nürnberg; Lukas Fiedler; Robert Hatala; Cesar Khazen
Journal:  Clin Cardiol       Date:  2020-08-14       Impact factor: 2.882

10.  Complications related to elective generator replacement of the subcutaneous implantable defibrillator.

Authors:  Willeke van der Stuijt; Anne-Floor B E Quast; Sarah W E Baalman; Koen C de Wilde; Tom F Brouwer; Arthur A M Wilde; Reinoud E Knops
Journal:  Europace       Date:  2021-03-08       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.